Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1978 1
1979 1
1980 3
1981 1
1983 4
1984 5
1985 7
1986 1
1987 6
1989 4
1990 11
1991 11
1992 5
1993 5
1994 2
1995 7
1996 11
1997 8
1998 9
1999 14
2000 14
2001 5
2002 10
2003 12
2004 9
2005 11
2006 19
2007 20
2008 20
2009 20
2010 20
2011 25
2012 25
2013 15
2014 28
2015 41
2016 24
2017 27
2018 34
2019 29
2020 38
2021 38
2022 28
2023 22
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

581 results

Results by year

Filters applied: . Clear all
Page 1
Sulfonylureas, First Generation.
[No authors listed] [No authors listed] 2018 Mar 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Mar 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644148 Free Books & Documents. Review.
The first generation sulfonylureas include acetohexamide, chlorpropamide, tolazamide and tolbutamide, oral hypoglycemic agents that are used in therapy of type 2 diabetes. ...
The first generation sulfonylureas include acetohexamide, chlorpropamide, tolazamide and tolbutamide, oral hypoglycemic …
Sulfonylureas.
[No authors listed] [No authors listed] 2018 Mar 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Mar 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643682 Free Books & Documents. Review.
The sulfonylureas are widely used and are generally considered a first line of medication therapy for type 2 diabetes. The sulfonylureas are divided into first and second generation agents, based upon their relative potency. ...
The sulfonylureas are widely used and are generally considered a first line of medication therapy for type 2 diabetes. …
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, Søndergaard AL, Tankova TI, Tentolouris N, Buse JB. Frías JP, et al. Lancet Diabetes Endocrinol. 2021 Sep;9(9):563-574. doi: 10.1016/S2213-8587(21)00174-1. Epub 2021 Jul 21. Lancet Diabetes Endocrinol. 2021. PMID: 34293304 Clinical Trial.
We aimed to investigate the efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in adults with inadequately controlled type 2 diabetes on a stable dose of metformin with or without a sulfonylurea. METHODS: We did a 40-week, randomised, active-controlled, pa …
We aimed to investigate the efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in adults with inadequately controlled type …
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Hallakou-Bozec S, et al. Diabetes Obes Metab. 2021 Mar;23(3):664-673. doi: 10.1111/dom.14277. Epub 2020 Dec 29. Diabetes Obes Metab. 2021. PMID: 33269554 Free PMC article. Review.
Imeglimin is an investigational first-in-class novel oral agent for the treatment of type 2 diabetes (T2D). ...This potential mode of action is unique and has been shown to differ from that of other major therapeutic classes, including biguanides, sulphonylureas and …
Imeglimin is an investigational first-in-class novel oral agent for the treatment of type 2 diabetes (T2D). ...This potential mode of …
Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study.
Pradhan R, Lu S, Yin H, Yu OHY, Ernst P, Suissa S, Azoulay L. Pradhan R, et al. BMJ. 2022 Nov 1;379:e071380. doi: 10.1136/bmj-2022-071380. BMJ. 2022. PMID: 36318979 Free PMC article.
PARTICIPANTS: Three active comparator, new user cohorts of patients starting the study drugs (GLP-1 receptor agonists, DPP-4 inhibitors, or SGLT-2 inhibitors) or sulfonylureas with a history of chronic obstructive pulmonary disease. The first cohort included …
PARTICIPANTS: Three active comparator, new user cohorts of patients starting the study drugs (GLP-1 receptor agonists, DPP-4 inhibito …
Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores.
Suissa S, Moodie EE, Dell'Aniello S. Suissa S, et al. Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):459-468. doi: 10.1002/pds.4107. Epub 2016 Sep 9. Pharmacoepidemiol Drug Saf. 2017. PMID: 27610604
We illustrate this approach using data from the UK's Clinical Practice Research Datalink to evaluate whether the newer glucagon-like peptide-1 receptor agonists (GLP-1 analogs) used to treat type 2 diabetes increase the risk of heart failure, in comparison with the older similarl …
We illustrate this approach using data from the UK's Clinical Practice Research Datalink to evaluate whether the newer glucagon-like peptide …
Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial.
Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Martin P, et al. JAMA. 2018 Nov 13;320(18):1889-1898. doi: 10.1001/jama.2018.16131. JAMA. 2018. PMID: 30422193 Free PMC article. Clinical Trial.
Patients included were adults aged 65 years and older who were prescribed 1 of 4 Beers Criteria medications (sedative-hypnotics, first-generation antihistamines, glyburide, or nonsteroidal anti-inflammatory drugs), recruited from 69 community pharmacies. ...C …
Patients included were adults aged 65 years and older who were prescribed 1 of 4 Beers Criteria medications (sedative-hypnotics, first …
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.
Xie Y, Bowe B, Xian H, Loux T, McGill JB, Al-Aly Z. Xie Y, et al. Lancet Diabetes Endocrinol. 2023 Sep;11(9):644-656. doi: 10.1016/S2213-8587(23)00171-7. Epub 2023 Jul 24. Lancet Diabetes Endocrinol. 2023. PMID: 37499675
The evidence base for the older antihyperglycaemic drug classes (DPP-4 inhibitors and sulfonylureas) is generally less well developed. Because most randomised trials evaluated one antihyperglycaemic medication versus placebo, a head-to-head comparative effectiveness …
The evidence base for the older antihyperglycaemic drug classes (DPP-4 inhibitors and sulfonylureas) is generally less well de …
Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy.
Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, Gissler M, Huybrechts KF, Kjerpeseth LJ, Leinonen MK, Pazzagli L, Zoega H, Seely EW, Patorno E, Hernández-Díaz S. Cesta CE, et al. JAMA Intern Med. 2024 Feb 1;184(2):144-152. doi: 10.1001/jamainternmed.2023.6663. JAMA Intern Med. 2024. PMID: 38079178 Free PMC article.
EXPOSURE: Periconceptional exposure was defined as 1 or more prescription fill of sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and sodium-glucose cotransporter 2 (SGLT2) inhibitors, or insulin (active comparat …
EXPOSURE: Periconceptional exposure was defined as 1 or more prescription fill of sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhib …
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV. Seferović PM, et al. Eur J Heart Fail. 2018 May;20(5):853-872. doi: 10.1002/ejhf.1170. Epub 2018 Mar 8. Eur J Heart Fail. 2018. PMID: 29520964 Free article. Review.
There are no specific limitations to HF treatment in T2DM. Subanalyses of trials addressing HF treatment in the general population have shown that all HF therapies are similarly effective regardless of T2DM. Concerning T2DM treatment in HF patients, most guidelines current …
There are no specific limitations to HF treatment in T2DM. Subanalyses of trials addressing HF treatment in the general population ha …
581 results